# Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

> **NCT06764056** · NA · NOT_YET_RECRUITING · sponsor: **Institut universitaire de cardiologie et de pneumologie de Québec, University Laval** · enrollment: 120 (estimated)

## Conditions studied

- Metabolic Associated Fatty Liver Disease
- Metabolic Associated-dysfunction Steatohepatitis (MASH)
- Obesity

## Interventions

- **DRUG:** semaglutide
- **OTHER:** Diet

## Key facts

- **NCT ID:** NCT06764056
- **Lead sponsor:** Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06764056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06764056, "Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06764056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*